Name: Tesamorelin
Brand: Egrifta
Availability: InStock

Question 1

How does tesamorelin differ from CJC-1295?

Accepted Answer

Both are modified GHRH analogs. Tesamorelin carries an N-terminal hexenoyl modification and is FDA-approved (Egrifta) for a specific indication. CJC-1295 uses different chemical modifications, is not approved, and remains a research peptide. Tesamorelin's clinical dataset — multiple randomized phase-3 trials — is substantially larger.

Question 2

Does tesamorelin cause fluid retention or joint pain like rhGH?

Accepted Answer

It can. The FDA label lists fluid retention — including edema, arthralgia, and carpal tunnel syndrome — as a warning, attributed to increased GH secretion; these reactions were either transient or resolved with discontinuation. Arthralgia, injection-site erythema and pruritus, extremity pain, peripheral edema, and myalgia were the most common adverse reactions (>5%).

Question 3

Can tesamorelin be used for fat loss in people without HIV?

Accepted Answer

The FDA indication is limited to reducing excess abdominal fat in HIV-infected adults with lipodystrophy, and the label states it is not indicated for weight-loss management. Its efficacy and safety for visceral fat reduction outside that population have not been established by the approval trials, so any such use is off-label and should involve a clinician.

Question 4

How does tesamorelin compare to GLP-1 agonists for fat loss?

Accepted Answer

They act on different targets and have not been compared head-to-head. GLP-1 agonists such as semaglutide are approved for weight management and act largely through appetite reduction. Tesamorelin is not indicated for weight loss; in HIV phase-3 trials it reduced visceral fat by about 15% over 26 weeks without a significant change in abdominal subcutaneous fat. The two serve different clinical purposes.

Question 5

Does tesamorelin improve liver fat?

Accepted Answer

In people with HIV and NAFLD, yes. In a randomized, double-blind trial (Stanley et al., Lancet HIV 2019; 61 participants), 2 mg daily for 12 months reduced hepatic fat fraction by MR spectroscopy by an absolute 4.1% more than placebo (a 37% relative reduction), and 35% of tesamorelin recipients versus 4% on placebo reached a fat fraction below 5%. It is not FDA-approved for this use, and longer-term effects on liver histology still need study.

Question 6

What IGF-1 level should be targeted on tesamorelin?

Accepted Answer

The label does not set a target. Because tesamorelin increases IGF-1 and the effects of prolonged elevation are unknown, the label calls for IGF-1 monitoring during therapy and suggests considering discontinuation in patients with persistent elevations (e.g., above 3 SDS). Interpretation should be done with the prescribing clinician using age-specific lab reference ranges.

Question 7

Does tesamorelin improve cognition?

Accepted Answer

One randomized, placebo-controlled trial (Baker et al., Archives of Neurology 2012) gave 1 mg/day tesamorelin or placebo for 20 weeks to 152 adults aged 55–87, including 66 with mild cognitive impairment. It reported a favorable overall effect on cognition, a positive effect on executive function, and only a non-significant trend for verbal memory, with similar effects in both groups. This has not led to an approved cognitive indication.

Question 8

How long does it take for tesamorelin to reduce belly fat?

Accepted Answer

In the phase-3 trials, visceral fat was measured at 26 weeks: about a 15% reduction versus placebo with 2 mg daily, reaching roughly 18% in patients who continued for 12 months. In patients switched to placebo after 6 months, the visceral-fat improvements were rapidly lost, so the effect appears to depend on continued treatment.

Question 9

Does tesamorelin affect blood sugar or insulin levels?

Accepted Answer

It can. The FDA label warns that glucose intolerance or diabetes may develop: in trials, HbA1c rose to 6.5% or higher by week 26 in 5% of tesamorelin recipients versus 1% on placebo. The label recommends evaluating glucose status before starting and monitoring periodically. The main phase-3 publications reported no clinically meaningful differences in average glucose parameters, but individual patients can be affected.

Question 10

How does tesamorelin compare to GLP-1/glucagon dual agonists like mazdutide for visceral and liver fat?

Accepted Answer

No trial has compared them directly. Tesamorelin works by stimulating endogenous GH release and has randomized-trial evidence for reducing visceral fat in HIV-associated lipodystrophy and liver fat in HIV-associated NAFLD. Incretin-based agonists act through appetite and metabolic pathways and are studied mainly for overall weight and glycemic outcomes. The two classes target different goals and populations.

Question 11

Can tesamorelin be combined with a GLP-1 agonist for body-composition goals?

Accepted Answer

This combination has not been tested in controlled trials, so its safety and benefit are unknown. Both drugs affect glucose metabolism — the tesamorelin label warns of glucose intolerance — so any combined use would require clinician oversight and glucose monitoring.

Dose Range	Clinical trials used 2 mg once daily; current labeled dose for the EGRIFTA WR formulation is 1.28 mg once daily (formulations are not interchangeable)
Origin / Manufacturer	Synthetic
Regulatory Status	FDA-approved (Egrifta)
Active Components	Tesamorelin acetate
Storage	EGRIFTA WR vial: room temperature 20–25°C, protected from light (per current FDA labeling)
Form Factor	Lyophilized vial with diluent

Tesamorelin

Specifications

Frequently Asked Questions

Sources & References

Related Peptides

CJC-1295 + Ipamorelin

Semaglutide